Correlation of soluble gp130 serum concentrations with arterial blood pressure

Journal of Hypertension

Volumn 27, Issue 3, 2009, Pages 527-534

  Inta, Ioana ^a   Weber, Daniela ^a   Grundt, Christina ^b   Veltkamp, Roland ^a   Winteroll, Susanne ^a   Auffarth, Gerd U ^a   Bettendorf, Markus ^a   Lemmer, Björn ^b   Schwaninger, Markus ^a,c  

^a Department of Neurology ^*  (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Arterial blood pressure; Intima media thickness; Sgp130; Spontaneously hypertensive rats; Vascular smooth muscle cells

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TELMISARTAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERIAL PRESSURE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTIMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROKE; TUNICA MEDIA;

EID: 67649562222     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831e9948     Document Type: Article

References (46)

1. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108:2993- 2999.
2. Peeters AC, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, Thien T. Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 2001; 31:31-36.
3. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945- 2951.
4. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 2006; 12:1623-1635.
5. Vazquez-Oliva G, Fernandez-Real JM, Zamora A, Vilaseca M, Badimon L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens 2005; 19:457-462.
6. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005; 46:735-739.
7. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110:1103-1107.
8. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19:1623-1629.
9. Takimoto Y, Aoyama T, Iwanaga Y, Izumi T, Kihara Y, Pennica D, et al. Increased expression of cardiotrophin-1 during ventricular remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002; 282:H896- H901.
10. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003; 21:1787-1803.
11. Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y, et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol 1991; 260:H1713-H1717.
12. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O'Donnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol 2007; 171:315-325.
13. Rose-John S, Neurath MF. IL-6 trans-signaling: the heat is on. Immunity 2004; 20:2-4.
14. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20.
15. Mullberg J, Dittrich E, Graeve L, Gerhartz C, Yasukawa K, Taga T, et al. Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett 1993; 332:174-178.
16. Diamant M, Rieneck K, Mechti N, Zhang XG, Svenson M, Bendtzen K, et al. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett 1997; 412:379-384.
17. AcalovschiD, Wiest T, Hartmann M,Farahmi M, Mansmann U,Auffarth GU, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 2003; 34:1864-1869.
18. Hitzler W, Bein G, Kasper R, Biscoping J, Kubanek B, Böck M, et al. Guidelines for the production of blood and blood fractions and for the usë of blood products. Dt Ärzteblatt 2001; 98:A3074- A3075.
19. Schwaninger M, Ringleb P, Annecke A, Winter R, Kohl B, Werle E, et al. Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol 2000; 247:687-690.
20. Lemmer B, Mattes A, Bohm M, Ganten D. Circadian blood pressure variation in transgenic hypertensive rats. Hypertension 1993; 22: 97-101.
21. Zuther P, Lemmer B. Chronos-Fit, Version 1.05. http://www.abpm-fit.de/ [2004].
22. Pummer S, Lemmer B. Dose-dependent effects of telmisartan on circadian rhythm in blood pressure and heart rate in spontaneously hypertensive rats (SHR). Dtsch Med Wochenschr 2000; 125 (Suppl 3):S39.
23. Inta I, Paxian S, Maegele I, Zhang W, Pizzi M, Spano P, et al. Bim and Noxa are candidates to mediate the deleterious effect of the NF-{kappa}B subunit RelA in cerebral ischemia. J Neurosci 2006; 26:12896- 12903.
24. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ,et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004; 24:8237-8244.
25. Giuliani N, Sansoni P, Girasole G, Vescovini R, Passeri G, Passeri M, et al. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol 2001; 36:547-557.
26. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
27. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999; 163:4583-4589.
28. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999; 97:189-198.
29. Wang Y. Fill a Gab(1) in cardiac hypertrophy signaling: search a missing link between gp130 and ERK5 in hypertrophic remodeling in heart. Circ Res 2003; 93:186-188.
30. Strandberg TE, Pitkala K. What is the most important component of blood pressure: systolic, diastolic or pulse pressure? Curr Opin Nephrol Hypertens 2003; 12:293-297.
31. Kurdi M, Randon J, Cerutti C, Bricca G. Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol Cell Biochem 2005; 269:95-101.
32. Gonzalez A, Ravassa S, Loperena I, Lopez B, Beaumont J, Querejeta R, et al. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens 2007; 25:2148-2157.
33. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002; 106:1442-1446.
34. Ancey C, Corbi P, Froger J, Delwail A, Wijdenes J, Gascan H, et al. Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine 2002; 18:199-205.
35. Hirota H, Izumi M, Hamaguchi T, Sugiyama S, Murakami E, Kunisada K, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels 2004; 19:237-241.
36. Romero DG, Plonczynski M, Vergara GR, Gomez-Sanchez EP, Gomez-Sanchez CE. Angiotensin II early regulated genes in H295R human adrenocortical cells. Physiol Genomics 2004; 19:106-116.
37. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004; 22:1141-1149.
38. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000; 275:29717-29723.
39. Mocchegiani E, Giacconi R, Cipriano C, Gasparini N, Bernardini G, Malavolta M, et al. The variations during the circadian cycle of liver CD1d-unrestricted NK1.1+TCR gamma/delta+ cells lead to successful ageing. Role of metallothionein/IL-6/gp130/PARP-1 interplay in very old mice. Exp Gerontol 2004; 39:775-788.
40. Gray SR, Robinson M, Nimmo MA. Response of plasma IL-6 and its soluble receptors during submaximal exercise to fatigue in sedentary middle-aged men. Cell Stress Chaperones 2008; 13:247-251.
41. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82:1120-1126.
42. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998; 161:6347-6355.
43. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268:160-167.
44. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171:3202-3209.
45. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583-588.
46. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-714.